Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. reports developments as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. Its news centers on oncology programs including CTIM-76, a CLDN6 x CD3 bispecific antibody; CT-95, a MSLN x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Recurring updates cover clinical and preclinical data, regulatory designations, scientific conference presentations, operating results, research and development spending, liquidity, investor-conference activity and equity-based employee inducement grants. CTIM-76 has received FDA Fast Track designation for platinum-resistant ovarian cancer, adding regulatory status to the company's solid-tumor development disclosures.
Context Therapeutics (Nasdaq: CNTX) announced a private placement, securing approximately $31.25 million from the sale of 5,000,000 shares of common stock and warrants to purchase an additional 5,000,000 shares. Each share and accompanying warrant are priced at $6.25. The placement is set to close on December 6, 2021, subject to usual conditions. The shares and warrants will not be registered under the Securities Act and may not be sold in the U.S. without registration or an exemption. Context is focused on innovating treatments for breast and gynecological cancers.
Context Therapeutics (Nasdaq: CNTX) announced that clinical data for ONA-XR will be presented at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The presentations will include primary results from the ONAWA trial, focusing on early-stage breast cancer, as well as updates from ongoing trials in metastatic breast cancer. ONA-XR targets progesterone receptor-positive cancers and is currently undergoing multiple Phase 1b and Phase 2 trials. The company aims to highlight the drug's potential impact on treatment outcomes.
Context Therapeutics has appointed Jennifer Minai-Azary as Chief Financial Officer and Alex Levit as Chief Legal Officer, as announced on November 1, 2021. This leadership change follows the company's recent debut on Nasdaq and aims to strengthen its position in developing treatments for hormone-driven women's cancers. Minai-Azary, with over 20 years of experience, previously served as CFO at Millendo Therapeutics, while Levit brings nearly two decades of legal expertise in the biopharma sector. Both executives are expected to drive the company's strategic growth and clinical milestones.
Context Therapeutics has initiated its Phase 2 trial, the SMILE Study, evaluating ONA-XR (onapristone extended release) in combination with fulvestrant for patients suffering from ER-positive, PR-positive, HER2-negative metastatic breast cancer who have previously progressed on endocrine therapies and CDK4/6 inhibitors. The trial aims to enroll up to 39 patients, focusing on overall response rate and other key metrics. The study is designed to explore ONA-XR's effectiveness in overcoming treatment resistance in this patient population.
Context Therapeutics (Nasdaq: CNTX) has successfully closed its initial public offering of 5,750,000 shares at $5.00 each, raising $28.75 million in gross proceeds. The offering included a full exercise of the underwriter's option to purchase an additional 750,000 shares. ThinkEquity served as the sole book-running manager. The registration statement became effective on October 19, 2021, with offerings made by means of a prospectus. Context is focused on developing treatments for hormone-driven breast and gynecological cancers.
Context Therapeutics Inc. (Nasdaq: CNTX) has priced its initial public offering (IPO) at $5.00 per share, aiming to raise $25.0 million through the sale of 5,000,000 shares. The underwriter has a 45-day option for an additional 750,000 shares. Trading is set to begin on the Nasdaq Capital Market on October 20, 2021, with the offering expected to close on October 22, 2021, pending customary conditions. The company focuses on advanced treatments for hormone-driven breast and gynecological cancers, with a robust clinical program for its lead candidate, onapristone extended release (ONA-XR).
Centrexion Therapeutics announced a successful raise of $40.5 million through convertible security investments from Lilly and Exome Asset Management, along with expanded lending from Solar Capital Partners. This capital will bolster Centrexion's pipeline of four clinical-stage drug candidates targeting chronic pain, including therapies in Phase 3 and Phase 2a trials. With over $75 million in cash post-fundraise, the company plans further in-licensing of promising mid-stage assets. The ongoing collaboration with Lilly further validates Centrexion's strategy in the pain management sector.